— Vertex Pharmaceuticals (NASDAQ: VRTX) reported third-quarter 2019 earnings of $1.23 per share, vs. $1.15 per share expected
— Total revenue grew 21% to $949.8 million, vs $950.9 million expected.
— Reiterated FY19 product revenues guidance of $3.70 – 3.75 billion. Non-GAAP effective tax rate outlook was also unchanged at 21-22%.
— VRTX shares were down 0.14% immediately following the announcement.
